[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Perrillo et al., 2004 - Google Patents

Comparison of quality of life, work productivity and medical resource utilization of peginterferon alpha 2a vs the combination of interferon alpha 2b plus ribavirin as …

Perrillo et al., 2004

View PDF
Document ID
660773319131947600
Author
Perrillo R
Rothstein K
Rubin R
Alam I
Imperial J
Harb G
Hu S
Klaskala W
Publication year
Publication venue
Journal of viral hepatitis

External Links

Snippet

The on‐treatment impact of interferon‐based therapies on quality of life (QOL), work productivity, and medical resource utilization has not been systematically studied. We evaluated the effects of treatment with peginterferon alpha (pegIFNα) 2a monotherapy and …
Continue reading at www.academia.edu (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/576—Immunoassay; Biospecific binding assay for hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data

Similar Documents

Publication Publication Date Title
Perrillo et al. Comparison of quality of life, work productivity and medical resource utilization of peginterferon alpha 2a vs the combination of interferon alpha 2b plus ribavirin as initial treatment in patients with chronic hepatitis C
Raison et al. Paroxetine for prevention of depressive symptoms induced by interferon‐alpha and ribavirin for hepatitis C
Gaeta et al. Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in ‘real world’patients with chronic hepatitis C
Lee et al. Comparison of a 6‐month course peginterferon α‐2b plus ribavirin and interferon α‐2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan
Everson et al. Sofosbuvir with velpatasvir in treatment-naive noncirrhotic patients with genotype 1 to 6 hepatitis C virus infection: a randomized trial
Foster Quality of life considerations for patients with chronic hepatitis C
Zeuzem et al. Grazoprevir–elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial
Van Thiel et al. Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse
Schaefer et al. Escitalopram for the prevention of peginterferon-α2a–associated depression in hepatitis C virus–infected patients without previous psychiatric disease: a randomized trial
Bruggmann et al. Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients
Butt et al. Hepatitis C treatment completion rates in routine clinical care
Sun et al. Randomised clinical trial: efficacy of peginterferon alfa‐2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance
Hiramatsu et al. Ribavirin dose reduction raises relapse rate dose‐dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha‐2b plus ribavirin
Jessner et al. Early viral kinetics on treatment with pegylated interferon‐α‐2a in chronic hepatitis C virus genotype 1 infection
Yu et al. A randomized trial of 24‐vs. 48‐week courses of PEG interferon α‐2b plus ribavirin for genotype‐1b‐infected chronic hepatitis C patients: a pilot study in Taiwan
Berg et al. Re‐treatment of chronic hepatitis C patients after relapse: efficacy of peginterferon‐alpha‐2a (40 kDa) and ribavirin
McHutchison et al. Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C
Tangkijvanich et al. Response‐guided therapy for patients with hepatitis C virus genotype 6 infection: a pilot study
Nguyen et al. Response to pegylated interferon and ribavirin in Asian American patients with chronic hepatitis C genotypes 1 vs 2/3 vs 6
Escudero et al. Pegylated α‐interferon‐2a plus ribavirin compared with pegylated α‐interferon‐2b plus ribavirin for initial treatment of chronic hepatitis C virus: Prospective, non‐randomized study
Childs-Kean et al. Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C
Raptopoulou et al. The effect of adherence to therapy on sustained response in daily or three times a week interferon alpha‐2b plus ribavirin treatment of naive and nonresponder chronic hepatitis C patients
De Rosa et al. Dose-dependent and genotype-independent sustained virological response of a 12 week pegylated interferon alpha-2b treatment for acute hepatitis C
Inoue et al. Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha‐2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses
Zaman et al. Peginterferon vs. standard interferon in the treatment of chronic hepatitis C